EuroPharma to enhance product efficacy with enteric coating
the US that will enable the delivery of ingredients in quantities
and better utilization by the body. Its first market outings:
products designed to block carbohydrates and fat, and in blood
sugar management supplements.
The proprietary technology was developed over a period of a year by an undisclosed European company and is the latest 'discovery' by EuroPharma, which makes it its mission to bring unique, extensively researched products to the US marketplace.
Terry Lemerond, founder and president of EuroPharma, was not able to disclose details of the technology just yet, but he did say that it "increases biological activity and ensures a greater amount of active ingredients reaching target areas of the body".
For example in the case of white kidney bean extract, which is used as a carbohydrate blocker, some people may be inclined to take large quantities as they do not know how much is actually getting through the harsh conditions of the stomach.
EuroPharma is working with a company on the development of a tablet that will ensure a precise dose of the bean extract is delivered; according to EuroPharma it makes it 120 times stronger than any other carb blocker on the market.
Other enteric tablet coatings are available on the market, but "nothing in the carb-blocking category", said Lemerond.
What is more, the company has patented such use of enteric coating.
Two other applications to which the technology has been applied so far are a fat blocker that improves lipase inhibition and blocks the absorption of fat; and a blood sugar management supplement.
True to EuroPharma's emphasis on science, both of these have been thoroughly researched. The former has been shown to result in 71 percent lower serum trigylcerides and 21 percent lower total cholesterol, and the latter in a 49 percent reduction in serum blood sugar levels in subjects with type-2 diabetes.
The technology has the potential to be applied to other ingredients too, and indeed with worldwide distribution rights EuroPharma is currently seeking companies that could use it to improve their product offering.
Lemerond is a fierce advocate of the role research must play in the supplements industry, and sets strong scientific standards for the products he represents.
"Science improves the quality of products on the market," he told NutraIngredients-USA.com. "We want companies to have a budget for R&D, and to have products that meet a high benchmark".
At next week's SupplySide East show in Secaucus, New Jersey, Lemerond will present a session entitled Product Development Insights that will Energize our Industry.
The 'how to' discussion will center around validating formulation with synergistic ingredients validated by science, as well as the importance of an R&D budget and the provision of safety data on products and ingredients.
